Stockreport

Immuron Receives U.S. Patent on Drug Composition to Treat Clostridium difficile

Immuron Limited - American Depositary Shares  (IMRN) 
US:NASDAQ Investor Relations: immuron.com/investor-centre/business-overview
PDF C. difficile remains a major medical problem, causing an estimated annual economic burden of more than USD $10 billion globally, with 28,000 deaths per year in the U.S. [Read more]